ArticleAACE endocrinology and diabetes
Two Cases of Iron-Induced Hypophosphatemia.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objective: Present 2 cases of severe hypophosphatemia related to ferric carboxymaltose infusions with a brief overview of the pathophysiology and factors that predispose certain patients to this phenomenon. Case Report: A 46-year-old male with history of hereditary hemorrhagic telangiectasias presented with severe progressive bilateral foot and leg pain as well as insufficiency fractures after initiating on ferric carboxymaltose infusions. Biochemical evaluation demonstrated severe hypophosphatemia and renal phosphate wasting. Discontinuation of further iron infusions led to resolution of symptoms and improvement in phosphate levels.Similarly, a 61-year-old male with history of Crohn disease and prior bowel resections was identified to have consistent hypophosphatemia after ferric carboxymaltose infusions. Discussion: Hypophosphatemic disorders due to renal phosphate wasting present a diagnostic challenge and morbidity to patients further exacerbated by delays in diagnosis and treatment. Intravenous iron infusions are commonly used to treat a variety of medical conditions. These treatments, especially ferric carboxymaltose, can cause severe FGF23 mediated renal phosphate wasting and osteomalacia. Conclusion: It is crucial for clinicians to recognize FGF23 mediated renal phosphate wasting in the setting of intravenous iron infusions. Patients with gastrointestinal malabsorption and secondary hyperparathyroidism can have sustained hypophosphatemia as a result of ferric carboxymaltose infusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.